Photocure ASA
ISIN: NO0010000045 | Ticker: PHO | LEI: 5967007LIEEXZXG8OW35
Country: Norway
Our story began in 1997 at our headquarters in Oslo, Norway. Photocure began with a focus on developing and improving photodynamic technology. Over the years our focus changed, still grounded in the world of photodynamic technology, we evolved our vision to become a bladder cancer speciality company.
In collaboration with our partners, we are dedicated to improving outcomes for patients all around the world. It’s a dedication that can be seen in our products and services, providing transformative solutions that improve the management of bladder cancer, as well as helping us become a global leader in the field.
For too long patients with bladder cancer have had limited options, leaving them living in fear of recurrence and progression. This is why we are The Bladder Cancer Company and why every single person at Photocure is focused on a single mission – making a continuous, positive impact on the lives of our patients, the people we work with, and society as a whole.
1993
Served areaWorldwide
HeadquartersHoffsveien 4, 0275 Oslo – Norway
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 776,047,000.00 | 789,648,000.00 | 719,034,000.00 |
| Noncurrent Assets | N/A | 363,801,000.00 | 376,459,000.00 | 360,808,000.00 |
| Property Plant And Equipment | N/A | N/A | 33,575,000.00 | 32,479,000.00 |
| Goodwill | N/A | 144,000,000.00 | 144,000,000.00 | 144,000,000.00 |
| Deferred Tax Assets | N/A | 49,879,000.00 | 53,003,000.00 | 55,120,000.00 |
| Current Assets | N/A | 412,246,000.00 | 413,189,000.00 | 358,226,000.00 |
| Current Trade Receivables | N/A | 43,097,000.00 | 47,980,000.00 | 47,164,000.00 |
| Other Current Receivables | N/A | 4,584,000.00 | 14,780,000.00 | 16,455,000.00 |
| Cash and cash equivalents | 125,320,000.00 | 334,887,000.00 | 322,895,000.00 | 268,073,000.00 |
| Equity And Liabilities | N/A | 776,047,000.00 | 789,648,000.00 | 719,034,000.00 |
| Equity | 208,590,000.00 | 508,132,000.00 | 502,633,000.00 | 462,733,000.00 |
| Issued Capital | N/A | 13,359,000.00 | 13,487,000.00 | 13,560,000.00 |
| Retained Earnings | N/A | 110,768,000.00 | 78,412,000.00 | 8,758,000.00 |
| Liabilities | N/A | 267,915,000.00 | 287,016,000.00 | 256,301,000.00 |
| Noncurrent Liabilities | N/A | 188,134,000.00 | 173,433,000.00 | 152,245,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 3,079,000.00 | 3,520,000.00 | 4,755,000.00 |
| Current Liabilities | N/A | 79,781,000.00 | 113,583,000.00 | 104,056,000.00 |
| Trade And Other Current Payables | N/A | 23,316,000.00 | 23,648,000.00 | 21,281,000.00 |
| Other Current Liabilities | N/A | 38,609,000.00 | 50,354,000.00 | 50,807,000.00 |
| Other Current Borrowings And Current Portion Of Other Noncurrent Borrowings | N/A | 12,500,000.00 | 36,580,000.00 | N/A |
| Line item in (nok) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 256,482,000.00 | 360,540,000.00 | 393,132,000.00 |
| Revenue From Contracts With Customers | 256,482,000.00 | 354,124,000.00 | 374,474,000.00 |
| Profit Loss From Operating Activities | -36,058,000.00 | -5,826,000.00 | -49,003,000.00 |
| Finance Income | 26,439,000.00 | 26,212,000.00 | 9,218,000.00 |
| Finance Costs | 23,607,000.00 | 34,822,000.00 | 30,591,000.00 |
| Profit Loss Before Tax | -33,226,000.00 | -31,656,000.00 | -71,134,000.00 |
| Income Tax Expense Continuing Operations | -10,823,000.00 | -759,000.00 | 723,000.00 |
| Profit (loss) | -22,403,000.00 | -30,897,000.00 | -71,857,000.00 |
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -22,403,000.00 | -30,897,000.00 | -71,857,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -13,269,000.00 | 2,144,000.00 | 1,000,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 19,292,000.00 | 24,127,000.00 | 24,378,000.00 |
| Adjustments For Provisions | N/A | 2,606,000.00 | 11,668,000.00 | 460,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 815,000.00 | -14,870,000.00 | 763,000.00 |
| Adjustments For Sharebased Payments | N/A | 7,881,000.00 | 12,665,000.00 | 22,176,000.00 |
| Other Adjustments For Noncash Items | N/A | -387,000.00 | -2,528,000.00 | -893,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | -94,000.00 | -314,000.00 | -2,777,000.00 |
| Cash Flows From Used In Operating Activities | N/A | 15,584,000.00 | 23,886,000.00 | -2,018,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 1,185,000.00 | 3,703,000.00 | 3,609,000.00 |
| Interest Received Classified As Investing Activities | N/A | 2,116,000.00 | 1,807,000.00 | 2,147,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -166,210,000.00 | -1,896,000.00 | -1,462,000.00 |
| Proceeds From Issuing Shares | N/A | 301,703,000.00 | 0.00 | N/A |
| Proceeds From Borrowings Classified As Financing Activities | N/A | N/A | -12,500,000.00 | -25,000,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 3,618,000.00 | 5,306,000.00 | 3,164,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 562,000.00 | 1,401,000.00 | 1,368,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 360,191,000.00 | -33,983,000.00 | -51,342,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 209,567,000.00 | -11,993,000.00 | -54,822,000.00 |
| Cash and cash equivalents | 125,320,000.00 | 334,887,000.00 | 322,895,000.00 | 268,073,000.00 |
Please note that some sums might not add up.
NO0010000045
LEI5967007LIEEXZXG8OW35
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.